Skip to main content
SpringerLink
Log in

Immune Responses to Vaccination

  • Chapter
  • First Online:
Vaccination of Immunosuppressed Children in Clinical Practice

Part of the book series: In Clinical Practice ((ICP))

  • 226 Accesses

Abstract

In this chapter, we explain the development of the immune response after vaccination, differentiating between the primary immune response (first exposure with the antigen) and the secondary immune response (secondary exposure with the antigen). We also explain why it is necessary to give booster doses of vaccines for long-term protection and describe the various subtypes of vaccines. Then, we discuss the various steps of the cellular interaction and activation of the various immune cells after vaccination, with the induction of long-lived plasma cells and memory B cells, as well as the possible cellular targets of the various immunosuppressive drugs. For each immunosuppressive drug, we detail which part of the immune response is affected and its consequences on the immune response to vaccination, including recommendations for immunization with non-live vaccines and live vaccines.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 64.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 84.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. McHeyzer-Williams LJ, McHeyzer-Williams MG. Antigen-specific memory B cell development. Annu Rev Immunol. 2005;23:487–513.

    Article  CAS  PubMed  Google Scholar 

  2. Blanchard-Rohner G. Vaccination in children with autoimmune disorders and treated with various immunosuppressive regimens: a comprehensive review and practical guide. Front Immunol. 2021;12(3021)

    Google Scholar 

  3. Visser LG. The immunosuppressed traveler. Infect Dis Clin N Am. 2012;26(3):609–24.

    Article  CAS  Google Scholar 

  4. Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med. 2004;351(26):2715–29.

    Article  CAS  PubMed  Google Scholar 

  5. Papp KA, Haraoui B, Kumar D, Marshall JK, Bissonnette R, Bitton A, et al. Vaccination guidelines for patients with immune-mediated disorders on immunosuppressive therapies. J Cutan Med Surg. 2019;23(1):50–74.

    Article  CAS  PubMed  Google Scholar 

  6. Blanchard-Rohner G, Pulickal AS, Jol-van der Zijde CM, Snape MD, Pollard AJ. Appearance of peripheral blood plasma cells and memory B cells in a primary and secondary immune response in humans. Blood. 2009;114(24):4998–5002.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Radetsky M. Smallpox: a history of its rise and fall. Pediatr Infect Dis J. 1999;18(2):85–93.

    Article  CAS  PubMed  Google Scholar 

  8. Plotkin SA, Orenstein WA, Offit PA, Edwards KM. Plotkin’s vaccines. 7th ed. Philadelphia, PA: Elsevier; 2018. p. 1720.

    Google Scholar 

  9. Graves PM, Deeks JJ, Demicheli V, Jefferson T. Vaccines for preventing cholera: killed whole cell or other subunit vaccines (injected). Cochrane Database Syst Rev. 2010;(8):CD000974.

    Google Scholar 

  10. Sinclair D, Abba K, Zaman K, Qadri F, Graves PM. Oral vaccines for preventing cholera. Cochrane Database Syst Rev. 2011;(3):CD008603.

    Google Scholar 

  11. Milligan R, Paul M, Richardson M, Neuberger A. Vaccines for preventing typhoid fever. Cochrane Database Syst Rev. 2018;(5):CD001261.

    Google Scholar 

  12. Lumbreras Areta M, Eberhardt CS, Siegrist CA, Martinez de Tejada B. Antenatal vaccination to decrease pertussis in infants: safety, effectiveness, timing, and implementation. J Matern Fetal Neonatal Med. 2019;32(9):1541–6.

    Article  PubMed  Google Scholar 

  13. Edwards KM, Decker MD. Pertussis vaccines. In: Plotkin SA, Orenstein WA, Offit PA, Edwards KM, editors. Plotkin’s vaccines. 7th ed. Philadelphia, PA: Elsevier; 2018. p. 711–61.

    Chapter  Google Scholar 

  14. Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA. 1999;282(7):677–86.

    Article  CAS  PubMed  Google Scholar 

  15. Staples JE, Monath TP, Gershman MD, Barrett ADT. Yellow fever vaccines. In: Plotkin SA, Orenstein WA, Offit PA, Edwards KM, editors. Plotkin’s vaccines. 7th ed. Philadelphia, PA: Elsevier; 2018. p. 1181–265.

    Chapter  Google Scholar 

  16. Demicheli V, Jefferson T, Ferroni E, Rivetti A, Di Pietrantonj C. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev. 2018;(2):CD001269.

    Google Scholar 

  17. Bresee J, Fry AM, Sambhara S, Cox NJ. Inactivated influenza vaccines. In: Plotkin SA, Orenstein WA, Offit PA, Edwards KM, editors. Plotkin’s vaccines. 7th ed. Philadelphia, PA: Elsevier; 2018. p. 456–88.

    Chapter  Google Scholar 

  18. Strebel PM, Papania MJ, Gastañaduy PA, Goodson JL. Measles vaccines. In: Plotkin SA, Orenstein WA, Offit PA, Edwards KM, editors. Plotkin’s vaccines. 7th ed. Philadelphia, PA: Elsevier; 2018. p. 579–618.

    Chapter  Google Scholar 

  19. Kaplan LJ, Daum RS, Smaron M, McCarthy CA. Severe measles in immunocompromised patients. JAMA. 1992;267(9):1237–41.

    Article  CAS  PubMed  Google Scholar 

  20. Demicheli V, Rivetti A, Debalini MG, Di Pietrantonj C. Vaccines for measles, mumps and rubella in children. Cochrane Database Syst Rev. 2012;(2):CD004407.

    Google Scholar 

  21. Rubin SA. Mumps vaccines. In: Plotkin SA, Orenstein WA, Offit PA, Edwards KM, editors. Plotkin’s vaccines. 7th ed. Philadelphia, PA: Elsevier; 2018. p. 663–88.

    Chapter  Google Scholar 

  22. Drijkoningen JJ, Rohde GG. Pneumococcal infection in adults: burden of disease. Clin Microbiol Infect. 2014;20(Suppl 5):45–51.

    Article  PubMed  Google Scholar 

  23. Klugman KP, Dagan R, Malley R, Whitney CG. Pneumococcal conjugate vaccine and pneumococcal common protein vaccines. In: Plotkin SA, Orenstein WA, Offit PA, Edwards KM, editors. Plotkin’s vaccines. 7th ed. Philadelphia, PA: Elsevier; 2018. p. 773–815.

    Chapter  Google Scholar 

  24. Grabenstein JD, Musher DM. Pneumococcal polysaccharide vaccines. In: Plotkin SA, Orenstein WA, Offit PA, Edwards KM, editors. Plotkin’s Vaccines. 7th ed. Philadelphia, PA: Elsevier; 2018. p. 816–40.

    Chapter  Google Scholar 

  25. Nanduri SA, Sutherland AR, Gordon LK, Santosham M. Haemophilus influenzae type B vaccines. In: Plotkin SA, Orenstein WA, Offit PA, Edwards KM, editors. Plotkin’s vaccines. 7th ed. Philadelphia, PA: Elsevier; 2018. p. 301–18.

    Chapter  Google Scholar 

  26. Lal H, Cunningham AL, Godeaux O, Chlibek R, Diez-Domingo J, Hwang SJ, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015;372(22):2087–96.

    Article  PubMed  Google Scholar 

  27. Cunningham AL, Lal H, Kovac M, Chlibek R, Hwang SJ, Diez-Domingo J, et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med. 2016;375(11):1019–32.

    Article  CAS  PubMed  Google Scholar 

  28. Harper DM, DeMars LR. HPV vaccines – a review of the first decade. Gynecol Oncol. 2017;146(1):196–204.

    Article  CAS  PubMed  Google Scholar 

  29. Luckett R, Feldman S. Impact of 2-, 4- and 9-valent HPV vaccines on morbidity and mortality from cervical cancer. Hum Vaccin Immunother. 2016;12(6):1332–42.

    Article  PubMed  Google Scholar 

  30. Henao-Restrepo AM, Camacho A, Longini IM, Watson CH, Edmunds WJ, Egger M, et al. Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola ça suffit!). Lancet. 2017;389(10068):505–18.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Pittet LF, Abbas M, Siegrist CA, Pittet D. Missed vaccinations and critical care admission: all you may wish to know or rediscover-a narrative review. Intensive Care Med. 2020;46(2):202–14.

    Article  PubMed  Google Scholar 

  32. Plotkin SL, Plotkin SA. A short history of vaccination. In: Plotkin SA, Orenstein WA, Offit PA, Edwards KM, editors. Plotkin’s vaccines. 7th ed. Philadelphia, PA: Elsevier; 2018. p. 1–15.

    Google Scholar 

  33. Obaro SK, Pugatch D, Luzuriaga K. Immunogenicity and efficacy of childhood vaccines in HIV-1-infected children. Lancet Infect Dis. 2004;4(8):510–8.

    Article  CAS  PubMed  Google Scholar 

  34. Menson EN, Mellado MJ, Bamford A, Castelli G, Duiculescu D, Marczynska M, et al. Guidance on vaccination of HIV-infected children in Europe. HIV Med. 2012;13(6):333–6. e1–14.

    Article  CAS  PubMed  Google Scholar 

  35. Goenka A, Kollmann TR. Development of immunity in early life. J Infect. 2015;71(Suppl 1):S112–20.

    Article  PubMed  Google Scholar 

  36. Siegrist CA. The challenges of vaccine responses in early life: selected examples. J Comp Pathol. 2007;137(Suppl 1):S4–9.

    Article  CAS  PubMed  Google Scholar 

  37. Belgium SHCo. Vaccination of Immunocompromised or chronically ill children and/or adults. In: Food Chain Safety and Environment SHC, editor. Belgium; 2019.

    Google Scholar 

  38. Wiedermann U, Sitte HH, Burgmann H, Eser A, Falb P, Holzmann H, et al. Guidelines for vaccination of immunocompromised individuals. Wien Klin Wochenschr. 2016;128(Suppl 4):337–76.

    Article  CAS  PubMed  Google Scholar 

  39. Wagner N, Assmus F, Arendt G, Baum E, Baumann U, Bogdan C, et al. Impfen bei Immundefizienz: Anwendungshinweise zu den von der Ständigen Impfkommission empfohlenen Impfungen. (IV) Impfen bei Autoimmunkrankheiten, bei anderen chronisch-entzündlichen Erkrankungen und unter immunmodulatorischer Therapie. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2019;62(4):494–515.

    Article  PubMed  Google Scholar 

  40. Bühler S HC. Background document on immune-mediated inflammatory diseases (IMID), module 2: vaccination in patients with inflammatory bowel diseases and other gastroenterological (auto)immune conditions. In: Immunisation SFACo, Federal Office of Public Health of Swizerland. 2017.

    Google Scholar 

  41. Heijstek MW, Ott de Bruin LM, Bijl M, Borrow R, van der Klis F, Kone-Paut I, et al. EULAR recommendations for vaccination in paediatric patients with rheumatic diseases. Ann Rheum Dis. 2011;70(10):1704–12.

    Article  CAS  PubMed  Google Scholar 

  42. Suresh S, Upton J, Green M, Pham-Huy A, Posfay-Barbe KM, Michaels MG, et al. Live vaccines after pediatric solid organ transplant: proceedings of a consensus meeting, 2018. Pediatr Transplant. 2019;9:e13571.

    Google Scholar 

  43. Verolet CM, Pittet LF, Wildhaber BE, McLin VA, Rodriguez M, Grillet S, et al. Long-term seroprotection of varicella-zoster immunization in pediatric liver transplant recipients. Transplantation. 2019;103(11):e355–e64.

    Article  PubMed  Google Scholar 

  44. Posfay-Barbe KM, Pittet LF, Sottas C, Grillet S, Wildhaber BE, Rodriguez M, et al. Varicella-zoster immunization in pediatric liver transplant recipients: safe and immunogenic. Am J Transplant. 2012;12(11):2974–85.

    Article  CAS  PubMed  Google Scholar 

  45. Eperon G, Buhler S, Enriquez N, Vaudaux B. The immunosuppressed traveler: vaccination guidelines. Rev Med Suisse. 2018;14(605):922–33.

    PubMed  Google Scholar 

  46. Bühler S, Eperon G, Ribi C, Kyburz D, van Gompel F, Visser LG, et al. Vaccination recommendations for adult patients with autoimmune inflammatory rheumatic diseases. Swiss Med Wkly. 2015;145:w14159.

    PubMed  Google Scholar 

  47. Glass CK, Saijo K. Nuclear receptor transrepression pathways that regulate inflammation in macrophages and T cells. Nat Rev Immunol. 2010;10(5):365–76.

    Article  CAS  PubMed  Google Scholar 

  48. Perretti M, D'Acquisto F. Annexin A1 and glucocorticoids as effectors of the resolution of inflammation. Nat Rev Immunol. 2009;9(1):62–70.

    Article  CAS  PubMed  Google Scholar 

  49. Pileggi GS, de Souza CB, Ferriani VP. Safety and immunogenicity of varicella vaccine in patients with juvenile rheumatic diseases receiving methotrexate and corticosteroids. Arthritis Care Res. 2010;62(7):1034–9.

    Article  CAS  Google Scholar 

  50. Heijstek MW, van Gageldonk PG, Berbers GA, Wulffraat NM. Differences in persistence of measles, mumps, rubella, diphtheria and tetanus antibodies between children with rheumatic disease and healthy controls: a retrospective cross-sectional study. Ann Rheum Dis. 2012;71(6):948–54.

    Article  CAS  PubMed  Google Scholar 

  51. Kanakoudi-Tsakalidou F, Trachana M, Pratsidou-Gertsi P, Tsitsami E, Kyriazopoulou-Dalaina V. Influenza vaccination in children with chronic rheumatic diseases and long-term immunosuppressive therapy. Clin Exp Rheumatol. 2001;19(5):589–94.

    CAS  PubMed  Google Scholar 

  52. Kasapcopur O, Cullu F, Kamburoglu-Goksel A, Cam H, Akdenizli E, Calykan S, et al. Hepatitis B vaccination in children with juvenile idiopathic arthritis. Ann Rheum Dis. 2004;63(9):1128–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Kiray E, Kasapcopur O, Bas V, Kamburoglu-Goksel A, Midilli K, Arisoy N, et al. Purified protein derivative response in juvenile idiopathic arthritis. J Rheumatol. 2009;36(9):2029–32.

    Article  PubMed  Google Scholar 

  54. Aikawa NE, Campos LM, Silva CA, Carvalho JF, Saad CG, Trudes G, et al. Glucocorticoid: major factor for reduced immunogenicity of 2009 influenza A (H1N1) vaccine in patients with juvenile autoimmune rheumatic disease. J Rheumatol. 2012;39(1):167–73.

    Article  CAS  PubMed  Google Scholar 

  55. Campos LM, Silva CA, Aikawa NE, Jesus AA, Moraes JC, Miraglia J, et al. High disease activity: an independent factor for reduced immunogenicity of the pandemic influenza a vaccine in patients with juvenile systemic lupus erythematosus. Arthritis Care Res. 2013;65(7):1121–7.

    Article  CAS  Google Scholar 

  56. Malleson PN, Tekano JL, Scheifele DW, Weber JM. Influenza immunization in children with chronic arthritis: a prospective study. J Rheumatol. 1993;20(10):1769–73.

    CAS  PubMed  Google Scholar 

  57. Chan ES, Cronstein BN. Methotrexate–how does it really work? Nat Rev Rheumatol. 2010;6(3):175–8.

    Article  CAS  PubMed  Google Scholar 

  58. Petty RA, Laxer RM, Lindsley CB, Wedderburn L, editors. Textbook of pediatric rheumatology. 7th ed. Philadelphia, PA: Elsevier; 2016.

    Google Scholar 

  59. Heijstek MW, Scherpenisse M, Groot N, Tacke C, Schepp RM, Buisman AM, et al. Immunogenicity and safety of the bivalent HPV vaccine in female patients with juvenile idiopathic arthritis: a prospective controlled observational cohort study. Ann Rheum Dis. 2014;73(8):1500–7.

    Article  CAS  PubMed  Google Scholar 

  60. Borte S, Liebert UG, Borte M, Sack U. Efficacy of measles, mumps and rubella revaccination in children with juvenile idiopathic arthritis treated with methotrexate and etanercept. Rheumatology (Oxford). 2009;48(2):144–8.

    Article  CAS  Google Scholar 

  61. Heijstek MW, Kamphuis S, Armbrust W, Swart J, Gorter S, de Vries LD, et al. Effects of the live attenuated measles-mumps-rubella booster vaccination on disease activity in patients with juvenile idiopathic arthritis: a randomized trial. JAMA. 2013;309(23):2449–56.

    Article  CAS  PubMed  Google Scholar 

  62. Heijstek MW, Ott de Bruin LM, Borrow R, van der Klis F, Kone-Paut I, Fasth A, et al. Vaccination in paediatric patients with auto-immune rheumatic diseases: a systemic literature review for the European League against Rheumatism evidence-based recommendations. Autoimmun Rev. 2011;11(2):112–22.

    Article  CAS  PubMed  Google Scholar 

  63. Gabay C, Bel M, Combescure C, Ribi C, Meier S, Posfay-Barbe K, et al. Impact of synthetic and biologic disease-modifying antirheumatic drugs on antibody responses to the AS03-adjuvanted pandemic influenza vaccine: a prospective, open-label, parallel-cohort, single-center study. Arthritis Rheum. 2011;63(6):1486–96.

    Article  CAS  PubMed  Google Scholar 

  64. Aytac MB, Kasapcopur O, Aslan M, Erener-Ercan T, Cullu-Cokugras F, Arisoy N. Hepatitis B vaccination in juvenile systemic lupus erythematosus. Clin Exp Rheumatol. 2011;29(5):882–6.

    PubMed  Google Scholar 

  65. Rondaan C, Furer V, Heijstek MW, Agmon-Levin N, Bijl M, Breedveld FC, et al. Efficacy, immunogenicity and safety of vaccination in adult patients with autoimmune inflammatory rheumatic diseases: a systematic literature review for the 2019 update of EULAR recommendations. RMD Open. 2019;5(2):e001035.

    Article  PubMed  PubMed Central  Google Scholar 

  66. van Assen S, Elkayam O, Agmon-Levin N, Cervera R, Doran MF, Dougados M, et al. Vaccination in adult patients with auto-immune inflammatory rheumatic diseases: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for vaccination in adult patients with auto-immune inflammatory rheumatic diseases. Autoimmun Rev. 2011;10(6):341–52.

    Article  PubMed  Google Scholar 

  67. Ritter ML, Pirofski L. Mycophenolate mofetil: effects on cellular immune subsets, infectious complications, and antimicrobial activity. Transpl Infect Dis. 2009;11(4):290–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Mok CC, Ho LY, Fong LS, To CH. Immunogenicity and safety of a quadrivalent human papillomavirus vaccine in patients with systemic lupus erythematosus: a case-control study. Ann Rheum Dis. 2013;72(5):659–64.

    Article  CAS  PubMed  Google Scholar 

  69. Hurd ER, Giuliano VJ. The effect of cyclophosphamide on B and T lymphocytes in patients with connective tissue diseases. Arthritis Rheum. 1975;18(1):67–75.

    Article  CAS  PubMed  Google Scholar 

  70. Ahlmann M, Hempel G. The effect of cyclophosphamide on the immune system: implications for clinical cancer therapy. Cancer Chemother Pharmacol. 2016;78(4):661–71.

    Article  CAS  PubMed  Google Scholar 

  71. Pittet LF, Verolet CM, McLin VA, Wildhaber BE, Rodriguez M, Cherpillod P, et al. Multimodal safety assessment of measles-mumps-rubella vaccination after pediatric liver transplantation. Am J Transplant. 2018.

    Google Scholar 

  72. Willcocks LC, Chaudhry AN, Smith JC, Ojha S, Doffinger R, Watson CJ, et al. The effect of sirolimus therapy on vaccine responses in transplant recipients. Am J Transplant. 2007;7(8):2006–11.

    Article  CAS  PubMed  Google Scholar 

  73. Zonneveld-Huijssoon E, Ronaghy A, Van Rossum MA, Rijkers GT, van der Klis FR, Sanders EA, et al. Safety and efficacy of meningococcal c vaccination in juvenile idiopathic arthritis. Arthritis Rheum. 2007;56(2):639–46.

    Article  PubMed  Google Scholar 

  74. Trollmo C, Gudmundsson S, Feltelius N, Rogberg S, Smedegard G, Klareskog L. Sulphasalazine inhibits human antigen-specific immune responses in vivo. Ann Rheum Dis. 2007;66(4):481–5.

    Article  CAS  PubMed  Google Scholar 

  75. Schrezenmeier E, Dorner T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol. 2020;16(3):155–66.

    Article  CAS  PubMed  Google Scholar 

  76. Holvast A, Huckriede A, Wilschut J, Horst G, De Vries JJ, Benne CA, et al. Safety and efficacy of influenza vaccination in systemic lupus erythematosus patients with quiescent disease. Ann Rheum Dis. 2006;65(7):913–8.

    Article  CAS  PubMed  Google Scholar 

  77. Elkayam O, Paran D, Caspi D, Litinsky I, Yaron M, Charboneau D, et al. Immunogenicity and safety of pneumococcal vaccination in patients with rheumatoid arthritis or systemic lupus erythematosus. Clin Infect Dis. 2002;34(2):147–53.

    Article  PubMed  Google Scholar 

  78. Groot N, Heijstek MW, Wulffraat NM. Vaccinations in paediatric rheumatology: an update on current developments. Curr Rheumatol Rep. 2015;17(7):46.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  79. Stoof SP, Heijstek MW, Sijssens KM, van der Klis F, Sanders EA, Teunis PF, et al. Kinetics of the long-term antibody response after meningococcal C vaccination in patients with juvenile idiopathic arthritis: a retrospective cohort study. Ann Rheum Dis. 2014;73(4):728–34.

    Article  PubMed  Google Scholar 

  80. Dell’Era L, Corona F, Daleno C, Scala A, Principi N, Esposito S. Immunogenicity, safety and tolerability of MF59-adjuvanted seasonal influenza vaccine in children with juvenile idiopathic arthritis. Vaccine. 2012;30(5):936–40.

    Article  PubMed  CAS  Google Scholar 

  81. Thalayasingam N, Isaacs JD. Anti-TNF therapy. Best Pract Res Clin Rheumatol. 2011;25(4):549–67.

    Article  CAS  PubMed  Google Scholar 

  82. Erguven M, Kaya B, Hamzah OY, Tufan F. Evaluation of immune response to hepatitis A vaccination and vaccine safety in juvenile idiopathic arthritis. J Chin Med Assoc. 2011;74(5):205–8.

    Article  PubMed  Google Scholar 

  83. Farmaki E, Kanakoudi-Tsakalidou F, Spoulou V, Trachana M, Pratsidou-Gertsi P, Tritsoni M, et al. The effect of anti-TNF treatment on the immunogenicity and safety of the 7-valent conjugate pneumococcal vaccine in children with juvenile idiopathic arthritis. Vaccine. 2010;28(31):5109–13.

    Article  CAS  PubMed  Google Scholar 

  84. Andrade P, Santos-Antunes J, Rodrigues S, Lopes S, Macedo G. Treatment with infliximab or azathioprine negatively impact the efficacy of hepatitis B vaccine in inflammatory bowel disease patients. J Gastroenterol Hepatol. 2015;30(11):1591–5.

    Article  CAS  PubMed  Google Scholar 

  85. Hagihara Y, Ohfuji S, Watanabe K, Yamagami H, Fukushima W, Maeda K, et al. Infliximab and/or immunomodulators inhibit immune responses to trivalent influenza vaccination in adults with inflammatory bowel disease. J Crohns Colitis. 2014;8(3):223–33.

    Article  PubMed  Google Scholar 

  86. Doherty TA, Brydges SD, Hoffman HM. Autoinflammation: translating mechanism to therapy. J Leukoc Biol. 2011;90(1):37–47.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  87. Jeyaratnam J, Ter Haar NM, Lachmann HJ, Kasapcopur O, Ombrello AK, Rigante D, et al. The safety of live-attenuated vaccines in patients using IL-1 or IL-6 blockade: an international survey. Pediatr Rheumatol Online J. 2018;16(1):19.

    Article  PubMed  PubMed Central  Google Scholar 

  88. Chioato A, Noseda E, Felix SD, Stevens M, Del Giudice G, Fitoussi S, et al. Influenza and meningococcal vaccinations are effective in healthy subjects treated with the interleukin-1 beta-blocking antibody canakinumab: results of an open-label, parallel group, randomized, single-center study. Clin Vaccine Immunol. 2010;17(12):1952–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  89. Kivitz AJ, Schechtman J, Texter M, Fichtner A, de Longueville M, Chartash EK. Vaccine responses in patients with rheumatoid arthritis treated with certolizumab pegol: results from a single-blind randomized phase IV trial. J Rheumatol. 2014;41(4):648–57.

    Article  CAS  PubMed  Google Scholar 

  90. Bingham CO III, Rizzo W, Kivitz A, Hassanali A, Upmanyu R, Klearman M. Humoral immune response to vaccines in patients with rheumatoid arthritis treated with tocilizumab: results of a randomised controlled trial (VISARA). Ann Rheum Dis. 2015;74(5):818–22.

    Article  CAS  PubMed  Google Scholar 

  91. Ribeiro AC, Laurindo IM, Guedes LK, Saad CG, Moraes JC, Silva CA, et al. Abatacept and reduced immune response to pandemic 2009 influenza A/H1N1 vaccination in patients with rheumatoid arthritis. Arthritis Care Res. 2013;65(3):476–80.

    Article  CAS  Google Scholar 

  92. Alten R, Bingham CO III, Cohen SB, Curtis JR, Kelly S, Wong D, et al. Antibody response to pneumococcal and influenza vaccination in patients with rheumatoid arthritis receiving abatacept. BMC Musculoskelet Disord. 2016;26(17):231.

    Article  CAS  Google Scholar 

  93. Migita K, Akeda Y, Akazawa M, Tohma S, Hirano F, Ideguchi H, et al. Effect of abatacept on the immunogenicity of 23-valent pneumococcal polysaccharide vaccination (PPSV23) in rheumatoid arthritis patients. Arthritis Res Ther. 2015;10(17):357.

    Article  CAS  Google Scholar 

  94. Oren S, Mandelboim M, Braun-Moscovici Y, Paran D, Ablin J, Litinsky I, et al. Vaccination against influenza in patients with rheumatoid arthritis: the effect of rituximab on the humoral response. Ann Rheum Dis. 2008;67(7):937–41.

    Article  CAS  PubMed  Google Scholar 

  95. Nagel J, Saxne T, Geborek P, Bengtsson AA, Jacobsen S, Svaerke Joergensen C, et al. Treatment with belimumab in systemic lupus erythematosus does not impair antibody response to 13-valent pneumococcal conjugate vaccine. Lupus. 2017;26(10):1072–81.

    Article  CAS  PubMed  Google Scholar 

  96. Chatham W, Chadha A, Fettiplace J, Kleoudis C, Bass D, Roth D, et al. A randomized, open-label study to investigate the effect of belimumab on pneumococcal vaccination in patients with active, autoantibody-positive systemic lupus erythematosus. Lupus. 2017;26(14):1483–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  97. Rehnberg M, Amu S, Tarkowski A, Bokarewa MI, Brisslert M. Short- and long-term effects of anti-CD20 treatment on B cell ontogeny in bone marrow of patients with rheumatoid arthritis. Arthritis Res Ther. 2009;11(4):R123.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  98. McCarthy CL, Tuohy O, Compston DA, Kumararatne DS, Coles AJ, Jones JL. Immune competence after alemtuzumab treatment of multiple sclerosis. Neurology. 2013;81(10):872–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  99. Brodmerkel C, Wadman E, Langley RG, Papp KA, Bourcier M, Poulin Y, et al. Immune response to pneumococcus and tetanus toxoid in patients with moderate-to-severe psoriasis following long-term ustekinumab use. J Drugs Dermatol. 2013;12(10):1122–9.

    CAS  PubMed  Google Scholar 

  100. Jamilloux Y, El Jammal T, Vuitton L, Gerfaud-Valentin M, Kerever S, Seve P. JAK inhibitors for the treatment of autoimmune and inflammatory diseases. Autoimmun Rev. 2019;18(11):102390.

    Article  CAS  PubMed  Google Scholar 

  101. Winthrop KL, Silverfield J, Racewicz A, Neal J, Lee EB, Hrycaj P, et al. The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis. Ann Rheum Dis. 2016;75(4):687–95.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of General Paediatrics, Immunology-Vaccinology, Geneva University Hospitals, Geneva, Switzerland

    Geraldine Blanchard-Rohner & Laure F. Pittet

Authors
  1. Geraldine Blanchard-Rohner
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Laure F. Pittet
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Geraldine Blanchard-Rohner .

Rights and permissions

Reprints and permissions

Copyright information

© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Blanchard-Rohner, G., Pittet, L.F. (2022). Immune Responses to Vaccination. In: Vaccination of Immunosuppressed Children in Clinical Practice . In Clinical Practice. Springer, Cham. https://doi.org/10.1007/978-3-031-04844-9_2

Download citation

  • DOI: https://doi.org/10.1007/978-3-031-04844-9_2

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-031-04843-2

  • Online ISBN: 978-3-031-04844-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation